Clinical review report: Apomorphine (Movapo) (Paladin Labs, Inc.)
The objective of this review was to perform a systematic review of the beneficial and harmful effects of apomorphine (Movapo) as an adjunct to oral anti-parkinson's disease (PD) medications to treat patients with advanced PD.
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, February 2018
|
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review was to perform a systematic review of the beneficial and harmful effects of apomorphine (Movapo) as an adjunct to oral anti-parkinson's disease (PD) medications to treat patients with advanced PD. |
|---|---|
| Item Description: | "Version: final." |
| Physical Description: | 1 PDF file (96 pages) illustrations |